Can plasminogen activators be improved?
Haber
E
E
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D005338:Fibrin Fibrinogen Degradation Products / Q000276:immunology; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010215:Papio; D010960:Plasminogen Activators / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C036309:fibrin fragment D; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator